836 Euclid Avenue
Suite 317
Lexington KY 40502-5223
Contact Information
Address 836 Euclid Avenue
Suite 317
Lexington, KY 40502 5223
Phone (502) 719-0544
Fax 502 589-5316
Contact Name Hannah Hardesty
At A Glance
IRS Ruling Year 2001
Former Names
Leukemia Society of America
Other ways to donate, support, or volunteer
Interested donors can mail checks to:  836 Euclid Ave, #317 / Lexington, KY 40502.
If interested in volunteering for events, office work, or donating in-kind items, please call:  502.719.0544
Financial Summary
Mission Statement The Leukemia & Lymphoma Society (LLS) exists to find cures and ensure access to treatments for blood cancer patients. Today, LLS is the world’s largest voluntary health agency dedicated to finding cures for leukemia, lymphoma, myeloma and other blood cancers.
Background Statement The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS is the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Our Key Priorities will ensure that:The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives. Research * Advance the diagnosis and treatment of blood cancers through continued funding of academic research, the therapy acceleration program and other special initiatives * Proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma & myeloma * Participate directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists Patient Services * Develop a services agenda for patients and their families to address their information and support needs * Inform blood cancer patients and improve access to the latest individual therapy options and blood cancer clinical trials * LLS is the key source of information and services for patients throughout their cancer journey Public Policy * Increase funding from non-LLS sources to accelerate the discovery and development of blood cancer therapies * Encourage an effective and science-driven regulatory system for efficient review of new blood cancer therapies * Ensure patients have insurance coverage for their treatments and well-coordinated and high quality cancer care
Impact Statement As of 2014, LLS has invested nearly $1 billion in research to advance therapies and save lives. From 2000 through 2013, almost 40 percent (31 of 81) of new anti-cancer drugs were FDA-approved for blood cancer patients, more first-ever approvals than for any other group of cancers, and many of these were advanced with funding from LLS. Many of these therapies are also helping patients with other cancers and other serious diseases. LLS is the leading source of free blood cancer information, education and support for patients, survivors, families and healthcare professionals. In North America, LLS’s co-pay assistance program has raised more than $200 million to date to help eligible blood cancer patients afford health-insurance premiums and prescription drug co-pays, assisting more than 36,000 patients since its inception in 2007. LLS also advocates for policies at the federal and state levels to accelerate the approval of new treatments and ensure access to quality, affordable and coordinated care.
Needs Statement Research: LLS is currently committed to hundreds of research projects across the globe. LLS makes these committments for multi year contracts without knowing the philanthropic landscape for future years. Every year we must ensure the promising projects are funded. Patient Access: Ensure patients have insurance coverage for their treatments and well-coordinated and high quality cancer care. Field Management: Increase public awareness of the impact blood cancer research is having on patients beyond those for whom they were first developed. Finance: Greatly reduce staff time spent gathering, consolidating, forecasting and budgeting, actual and operational data. Patient Services: Develop a services agenda for patients and their families to address their information and support needs.
CEO/Executive Director Statement
The Leukemia & Lymphoma Society - KY Chapter, is the foremost organization working to eradicate the blood cancers from the earth.  We are focused on two areas to accomplish this mission:  Cures and Access. 
We have dedicated more than $1 billion to world class research.  Survival rates have reached all time highs (80-90% depending on the specific disease) due to the work of LLS and our incredible volunteers.  Some blood cancers can now be treated with just a pill - no more chemo or radiation (CML and CLL).  But there are still many blood cancers with survival rates below 50% (AML & MM); and that is unacceptable to us.
Access for all patients to receive quality cancer care is of vital importance to LLS.  We have a travel assistance fund and a co-pay assistance fund.  In the fiscal years 2013 & 2014, the KY Chapter gave more than $1 million directly to patients and families in our state battling these diseases; helping them pay for treatments/medicines and supporting them in their travel to a quality cancer care facility. 
LLS is different from many organizations because we focus on Cures and Access.  And we won't stop until all cure rates are 100% and everyone who needs care will receive it, no matter the obstacles before them. 
Thank you for your support of our mission to cure the blood cancers and improve the quality of life of all patients and their families.
For cures,
Shane Stuber
Executive Director
LLS - KY Chapter
Board Chair Statement
The KY Chapter of LLS is excited to be leading the fight against blood cancers.  Our Chapter has great success with our Light The Night, Team In Training, and Pennies for Patients campaigns.  These monies have stayed in KY to serve those needing access to quality cancer care. 
The biggest challenge LLS has in the state is letting people know about the resource that 'is' LLS.  We are addressing this by developing stronger relationships with oncology doctors, nurses, and social workers in every corner of the state.  We have also stepped up our social media and electronic media strategies to further educate the public on LLS and what we're doing to make the world a healthier place. 
I first became involved with LLS because I wanted to train for a marathon and chose to do so with Team In Training. I learned so much from everyone involved, especially the individuals who were training....and were survivors!  They taught me that they were success stories but not all the stories are successful.  So, I became motivated to help this organization accomplish this daunting mission.  When cancer is cured, I want to say that I had a small part in making that happen.  And anyone who gets involved with LLS will be able to say the same thing!
It's going to take millions of people, pulling in the same direction to change the tides of cancer in the world.  Thank you for your consideration of support, in whatever way works for you. 
Marty Driskell
LLS - KY Chapter
Board Chair
Service Categories
Secondary Organization Category Education / Research Institutes & Public Policy Analysis
Geographic Areas Served
Throughout the United States
LLS impacts patients and their families through their 61 chapters across the United States and Canada. The KY Chapter serves 117 counties across the Bluegrass State.   
Impact Questions
GoalsHelpWhat is the organization aiming to accomplish? This is the organization's ultimate goal for intended impact.
LLS is trying to eradicate the world of all types of blood cancers (i.e. leukemia, lymphoma, Hodgkin's disease, myeloma).  There are more than 1.1 million people in the U.S. who are currently battling a blood cancer.  Our goal is to help direct resources to the best research doctors in the country who can take us closer to our ultimate goal. 
In the past 10 years, many blood cancers survival rates have increased at least 10-20%.  At this rate, I anticipate most blood cancers will have a survival rate of over 80% by 2025. 
Another goal is to ensure all patients, regardless of their personal resources, will have everything they need to secure top cancer care.  That is why we continue to grow our Co-Pay Assistance and Travel Assistance funds. 
No research has proven exactly what causes blood cancers.  They don't appear to be genetic.  And we don't know what causes these cells in our body to go rogue and begin causing damage.  So, we have no choice but to continue to find cures; and hopefully ones that cause less damange than chemo and radiation. 
StrategiesHelpWhat are the organization's strategies for its stated long-term goals?
In the U.S. right now, LLS is funding more than 200 researchers.  Each one is focused on different types and sub-types of these diseases.  We currently know there are over 150 sub-types of blood cancers.  Our research has helped us identify these sub-types and their characteristics.  Now, the goal is to find what minimally toxic treatments work best for each sub-type.  The only way we'll be able to beat all blood cancers is by understanding each sub-type and finding the proper way to beat it!
Of course, along the way we will most certainly find other sub-types.  And this is a wonderful thing because it will allow us to understand our enemy and defeat it!
CapabilitiesHelpWhat are the organization’s capabilities for doing this? What resources, capacities, and connections support its progress towards long-term goals?
We have an amazing network of researchers around the country and the world, all fighting for the same mission.  We have a unique ability to require our researchers to share their information and insights with LLS and we are becoming a central storage and processing station for blood cancer research information.  We have a wonderful relationship with the FDA (Food & Drug Administration) at the Federal level.  Of the 10 drugs to receive FDA Breakthrough Approval, half have been blood cancer drugs, supported by LLS. 
IndicatorsHelpHow will the organization know if it is making progress? What are the key qualitative and quantitative indicators against which the organization assesses its progress toward its intended impact?
We will simply know how much progress we are making by the sheer number of patients who become survivors each year, based on all the national indicators.  We know survival rates continue to go up and more people receive money from LLS for co-pay and travel assistance. 
The two most deadly blood cancers are AML and Multiple Myeloma.  LLS is shifting our portfolio to help further the advancement for quality treatments of those two, awful diseases.  Positive milestones would be for those two diseases to finally hit that 50% survival rate.  We are probably 3-5 years from that milestone.  However, what tends to happen is rapid progress once that 50% milestone is reached. 
ProgressHelpWhat has and hasn’t been accomplished so far?
Cure rates for children with ALL (the most common childhood leukemia) is 90+%.  Cure rates for Hodgkins and non-Hodgkins lymphomas are over 80%.   The adult leukemias (CML and CLL) have a survival rate of more than 95% & 80%, respectively. 
What we haven't accomplished yet, from a survival rate standpoint, is reaching a 50% survival rate for Acute Myeloid Leukemia (AML) and Multiple Myeloma.  There is still much work to be done.
We have also accomplished reaching the $1 million mark in money given directly back to patients and families in the KY Chapter area.  These monies have been used to help patients with co-pay and travel assistance. 
Blood cancer diagnoses are not slowing down so we will need to continue to raise money to help more patients each year gain quality access to cancer care. 
Board Chair
Board Chair Mr. Marty Driskell
Company Affiliation UPS
Term July 2013 to June 2015
Board Members
Patty Benz KORT RehabVoting
Marty Driskell UPSVoting
Allene Gold JCPS (Public School System)Voting
Dr Geetha Joseph Baptist Hospital & CBCVoting
Joseph Kron Attorney / Real EstateVoting
Aimee McCaa Norton HealthcareVoting
Dr Cesar Rodriguez UofL Healthcare / KY One HealthcareVoting
Diahanna Vallentine Waddell & Reed - InvestmentsVoting
Jennifer Washle Bisig Impact GroupVoting
Board Demographics - Ethnicity
African American/Black 2
Asian American/Pacific Islander 0
Caucasian 5
Hispanic/Latino 1
Native American/American Indian 1
Other 0 0
Board Demographics - Gender
Male 3
Female 6
Unspecified 0
Board Term Lengths 3
Board Term Limits 3
Board Meeting Attendance % 84%
Written Board Selection Criteria? Under Development
Written Conflict of Interest Policy? Yes
Percentage Making Monetary Contributions 100%
Percentage Making In-Kind Contributions 100%
Constituency Includes Client Representation Yes
Number of Full Board Meetings Annually 6
Board Co-Chair
Board CoChair Diahanna Vallentine
Company Affiliation Waddell & Reed
Term July 2014 to June 2015
CEO/Executive Director
Executive Director Mr. Shane Stuber
Term Start Mar 2013
Shane Stuber is the Executive Director of the KY Chapter of the Leukemia & Lymphoma Society.  He has been in fundraising in the state of KY for nearly 15 years.  He worked for LLS from 2000-2003.  Since that time, he gained experience with Big Brothers Big Sisters, Hosparus (a regional hospice-care provider), the City of Louisville, and with the Frazier History Museum.  Shane has had experience managing staff and hundreds of volunteers in many areas.  He brings a passion to LLS due to losing a family member to a leukemia in 2001. 
Full Time Staff 5
Part Time Staff 6
Volunteers 700
Contractors 0
Retention Rate 80%
Staff Demographics - Ethnicity
African American/Black 1
Asian American/Pacific Islander 0
Caucasian 8
Hispanic/Latino 0
Native American/American Indian 0
Other 0 1
Staff Demographics - Gender
Male 2
Female 8
Unspecified 0
Formal Evaluations
CEO Formal Evaluation Yes
CEO/Executive Formal Evaluation Frequency Annually
Senior Management Formal Evaluation Yes
Senior Management Formal Evaluation Frequency Annually
NonManagement Formal Evaluation Yes
Non Management Formal Evaluation Frequency Annually
The Leukemia & Lymphoma Society offers a comprehensive set of services to patients and families touched by blood cancers.  LLS offers newly diagnosed patients the opportunity to speak with a survivor volunteer that will help guide them in their cancer journey.  This program is called First Connection.  LLS also offers many support groups, disease-specific.  Also, we offer co-pay assistance and travel assistance, for those across the state of KY who qualify.  We will serve more than 4,400 blood cancer patients in the state of KY in 2015. 
Budget 97,128
Population Served , ,
Description The LLS Office of Public Policy is charged with pursuing LLS's mission through advocacy aimed at governmental decision-makers. After decisive victories in 2013, LLS will continue to focus on using advocacy to work toward a cure and improve the lives of blood cancer patients in 2014 and beyond.
Category Advocacy
Population Served None, None, None
Program Comments
CEO Comments
The KY Chapter of LLS is proud to offer world-class programs for patients and families battling any of the blood cancers.  From first diagnosis to the end of the fight, LLS is there to support patients will anything they need.  We are proud to say that all of the funds KY has raised in the past three years has stayed in KY, helping those that truly need it. 
Shane Stuber
Executive Director
LLS - KY Chapter
Plans & Policies
Organization has a Fundraising Plan? Under Development
Organization has a Strategic Plan?
Management Succession Plan? No
Organization Policy and Procedures Yes
Nondiscrimination Policy Yes
Whistleblower Policy Yes
Document Destruction Policy Yes
Fiscal Year
Fiscal Year Start July 01, 2014
Fiscal Year End June 30, 2015
Projected Revenue $1,692,041.00
Projected Expenses $764,466.00
Spending Policy N/A
Detailed Financials
Revenue and ExpensesHelpFinancial data for prior years is entered by foundation staff based on the documents submitted by nonprofit organizations.Foundation staff members enter this information to assure consistency in the presentation of financial data across all organizations.
Fiscal Year201520142013
Total Revenue$281,628,930$310,095,987$290,358,467
Total Expenses$277,443,057$317,198,282$306,978,665
Revenue Less Expenses$4,185,873($7,102,295)($16,620,198)
Revenue SourcesHelpThe financial analysis involves a comparison of the IRS Form 990 and the audit report (when available). Revenue from foundations and corporations may be included in individual contributions when not itemized separately.
Fiscal Year201520142013
Foundation and
Corporation Contributions
Government Contributions$0$0$0
Individual Contributions$119,854,485$136,594,740--
Investment Income, Net of Losses$1,877,457$1,200,545$2,256,195
Membership Dues$0$0$0
Special Events$154,436,727$163,590,328$161,261,897
Revenue In-Kind$969,388$890,755$1,094,571
Expense Allocation
Fiscal Year201520142013
Program Expense$205,794,613$240,600,749$234,466,765
Administration Expense$29,234,781$26,282,722$24,454,067
Fundraising Expense$42,413,663$50,314,811$48,057,833
Payments to Affiliates------
Total Revenue/Total Expenses1.020.980.95
Program Expense/Total Expenses74%76%76%
Fundraising Expense/Contributed Revenue15%17%17%
Assets and Liabilities
Fiscal Year201520142013
Total Assets$214,485,806$242,581,527$236,325,556
Current Assets$64,190,974$40,020,408$37,462,100
Long-Term Liabilities$0$0$0
Current Liabilities$116,963,860$145,444,419$135,316,123
Total Net Assets$97,521,946$97,137,108$101,009,433
Form 990s
2015 Form 990
2014 Form 990
2013 LLS 990
2012 LLS 990
2011 LLS 990
2010 Form 990
2009 Form 990
2008 Form 990
Capital Campaign
Currently in a Capital Campaign? No
State Registration Yes
Foundation Staff Comments

This organization is under the charitable umbrella of the national organization, the Leukemia & Lymphoma Society. The Leukemia & Lymphoma Society Lexington Chapter's financials are included the national organization's 990s.

Address 836 Euclid Avenue
Suite 317
Lexington, KY 405025223
Primary Phone 502 719-0544
Contact Email hannah.hardesty@lls.org
CEO/Executive Director Mr. Shane Stuber
Board Chair Mr. Marty Driskell
Board Chair Company Affiliation UPS